Izinova

Quick links to important sections

Izinova

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Izinova

Quick Facts

Property Description
Active ingredient Magnesium Sulfate, Potassium Sulfate, Sodium Sulfate
Form Concentrate for Oral Solution (Oral Liquid)
Pharmacological class Osmotic Laxative / Saline Purgative
Common use Bowel cleansing prior to procedures
Origin Synthetic / Mineral-derived (Ionic salts)

The medicine Izinova is an intensive, prescription-only combination medicine specifically designed for complete bowel cleansing prior to medical procedures. It is formally classified as an Osmotic Laxative and a Saline Purgative, a categorization that is clinically recognized for its efficacy in producing rapid intestinal evacuation.


What Type of Medicine is Izinova and Its Classification?

Izinova is a specialized Saline Purgative developed as a Concentrate for Oral Solution for the necessary process of lavage colique. The formulation utilizes a potent, osmotic principle to achieve a rapid, medically complete evacuation of the colon. These triple-salt preparations are recognized as an effective method for inducing the necessary catharsis required in clinical settings. This classification confirms the drug's specialized, short-term role, contrasting it with common laxatives used for chronic conditions.

Composition: A Combination of Sulfate Electrolytes

The active ingredient(s) in Izinova consist of a concentrated, unique blend of three distinct sulfate electrolyte minerals: Magnesium Sulfate, Potassium Sulfate, and Sodium Sulfate. The product is a synthetic/mineral-derived formulation presented as an oral liquid concentrate. This triple-salt system strategically minimizes the necessary fluid volume for administration.

Primary Purpose: Inducing Comprehensive Bowel Cleansing

The singular purpose of Izinova is to ensure a thorough and complete evacuation of the gastrointestinal tract, known as bowel cleansing. This preparation is required to facilitate clear visualization during procedural work. A typical use scenario involves preparation for a surgical intervention or an endoscopic exploration where the colon must be entirely clear of solid contents. The clinical success of the procedure relies heavily on achieving this preparatory state.

What side effects are possible with Izinova ?

Possible Side Effects and Safety Information for Izinova

The safety profile for Izinova (a bowel cleanser containing sulfate salts) is based on official government regulatory documentation, defining both common expectations and significant risks.

Frequency and Types of Adverse Reactions

The majority of documented adverse reactions are mild-to-moderate and related to the product's intended action.

Classification Common Examples Documented System Affected
Very Common Abdominal distension, abdominal pain, nausea, vomiting Gastrointestinal Disorders
Common Fatigue, headache General / Nervous System

Adverse reactions are formally categorized using standardized frequency bands (e.g., Very Common, Common) as defined in regulatory texts.

Serious Safety Risks and Restrictions

The most clinically significant risk is the potential for serious electrolyte abnormalities (such as hypernatremia or hypokalemia) and dehydration. The risk of these imbalances necessitates careful attention, especially in vulnerable patient groups.

Safety Restrictions (Contraindications): Izinova must not be used if a patient has specific severe pre-existing conditions. These restrictions include, but are not limited to, congestive heart failure, severe renal insufficiency, established gastrointestinal obstruction, ileus, or toxic colitis. The safety documentation dictates that adequate fluid intake, as prescribed, is essential to minimize the risk of dehydration and maintain the overall safety profile.

Population-Specific Considerations: Specific safety considerations are documented for use in older adults and individuals with pre-existing heart or kidney impairment. Regulatory documentation also exists for a specific adolescent age subgroup (12 to 17 years).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Izinova (triple-sulfate oral solution) is a risk primarily due to the potent osmotic action, which can lead to severe complications resulting from excessive fluid loss and electrolyte disturbances, as documented in official regulatory labeling.

Documented Overdose Manifestations and Outcomes

Overdose or misuse can result in severe volume contraction (dehydration) and significant abnormalities in electrolytes, such as hyponatremia and hypokalemia. These conditions are officially associated with serious adverse outcomes, including cardiac arrhythmias, seizures, loss of consciousness, and the risk of acute renal impairment or kidney failure.

When to Seek Immediate Medical Attention

The official guidance requires patients to seek immediate medical attention for any symptoms suggesting severe systemic complications. These critical signs include developing an irregular heartbeat, experiencing a seizure, or exhibiting signs of severe dehydration, such as minimal urination or extreme dizziness.

Supportive Actions and Monitoring

There is no specific antidote documented for an overdose of this sulfate preparation. Management is symptomatic and supportive, focusing on the immediate correction of any confirmed fluid and electrolyte abnormalities. Special monitoring, such as pre-dose and post-procedure electrocardiograms (ECGs), should be considered by a healthcare provider for patients with pre-existing heart conditions who may be at increased risk of serious cardiac arrhythmias.

Therapeutic Uses of Izinova

What Izinova Treats: Main Uses and Benefits

This medication is used to manage the acute condition of a waste-filled colon by providing intense, rapid clearance, an action that results in complete emptying. The primary therapeutic focus is on achieving the complete emptying of the large intestine. This process is applied to help create the conditions necessary for clear visualization.

This process for thorough clearing is commonly used in preparation for medical procedures such as a colonoscopy, endoscopy, or certain surgical preparations. Izinova supports the management of acute symptoms that interfere with examination by providing the necessary conditions for your healthcare provider to proceed with the medical procedure.

“This preparation process helps address the symptomatic need for bowel clearing, which supports the necessary diagnostic environment.”

This application is applied across domains where short-term symptomatic assistance is appropriate, primarily to address the need for significant bowel clearing and to help ease the physical strain associated with an uncleared digestive tract.

Quick Fact: Relief for Acute Bowel Symptoms
This medication is applied in clinical settings that involve acute, procedure-specific symptomatic patterns, supporting functional stability during a necessary preparation phase.

Regulatory References

  1. NIH MedlinePlus overview on bowel cleansers

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Izinova?

The population eligibility rules for Izinova (a triple-sulfate oral solution) are strictly defined by regulatory authorities and based on a patient’s gastrointestinal health, core organ function, and age.

Contraindications: Who Must Not Use This Medicine

The medicine is contraindicated and must not be used in patients with the following severe conditions, as the osmotic action of the salts could cause harm:

  • Gastrointestinal Obstruction: Bowel perforation, ileus, gastric retention, toxic colitis, or toxic megacolon.
  • Organ Failure: Severe renal impairment or congestive heart failure.
  • Other: Known hypersensitivity or allergy to any component of the formulation.

Age and Population Restrictions

Population Official Eligibility Status
Adults (ge 18) Approved for colon cleansing prior to procedure.
Children (lt 12) Safety and effectiveness have not been established.
Adolescents (ge 12) Approved for use.
Older Adults (ge 65) Use requires caution due to an increased risk of fluid and electrolyte abnormalities.

Conditional Use and Limitations

Official labeling requires caution or special monitoring for several patient groups. Use is restricted until pre-existing severe fluid and electrolyte imbalances are corrected. Additionally, patients at risk of arrhythmias, seizures, or those with severe active ulcerative colitis, gout, or other uric acid disorders should be treated with caution.

  • Pregnancy and Lactation: Due to a lack of adequate human studies, use during pregnancy or breastfeeding is allowed only if the potential benefit is determined to outweigh the potential risk, as decided by a healthcare provider.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Izinova (a triple-salt sulfate osmotic laxative) has a regulatory-documented interaction profile structured around two primary effects: reduced systemic absorption of oral drugs and the risk of fluid and electrolyte disturbances. All interactions outlined are based strictly on official governmental prescribing information.

Documented Interaction Patterns

Interaction Type Affected Substances / Outcome Restrictions
Absorption Most oral medications; decreased plasma concentration (Cmax/AUC). Timing Separation Required
Pharmacodynamic Diuretics, ACE Inhibitors, ARBs, NSAIDs; risk of exacerbated serum chemistry abnormalities. Use with Caution
Contraindication Stimulant Laxatives (e.g., Bisacodyl, Senna); risk of mucosal injury. Co-administration Prohibited

Mandatory Administration Timing Rules

Due to the rapid acceleration of gastrointestinal transit, most oral medications must not be taken within one hour of beginning Izinova administration. Specific cation-binding agents, including Digoxin, Chlorpromazine, Iron supplements, and certain Antibiotics (Tetracyclines, Fluoroquinolones), require a stricter separation interval: they must be administered at least 2 hours before or 6 hours after Izinova to ensure proper systemic exposure. Alcohol consumption is restricted during the preparation period due to the heightened risk of dehydration.

Population-Specific Notes

The severity of fluid and electrolyte-altering interactions is noted to be greater in patients with Renal Impairment or pre-existing Cardiac Arrhythmias.

Mechanism of Action

The Mechanism of Action: Osmotic Purgation

Izinova's mechanism of action is purely physicochemical, leveraging the principles of osmosis to produce a rapid, high-volume fluid evacuation. Its action is driven by the concentrated, non-absorbed nature of its triple-salt formulation, affecting local fluid dynamics and intestinal motility.

Generating the Intraluminal Osmotic Gradient

The active ingredients—magnesium, potassium, and sodium sulfates—act in synergy to establish a powerful hypertonic environment within the intestinal lumen. The key mechanistic step is the poor absorption of the sulfate anion ( SO4^2-) and the magnesium cation ( Mg^2+), which establishes a significant osmotic gradient across the intestinal epithelial barrier. This gradient continuously drives water from the body's circulation into the bowel lumen, increasing the fluid content of the gut.

Initiating Volume-Mediated Peristalsis

The massive influx and retention of water immediately elevates the intraluminal volume, causing significant distention (stretching) of the colonic wall. This physical stretching is the direct stimulus that activates the mechanoreceptors of the Enteric Nervous System (ENS). The ENS, in turn, triggers high-amplitude, propulsive motor contractions, which are the motor events required for the transit of the large volume of liquid contents. The final physiological consequence is a rapid, high-volume, watery evacuation (catharsis).

Dosage and Administration Information

Izinova (sodium sulfate, magnesium sulfate, potassium sulfate) is an oral solution concentrate intended for bowel cleansing in adults prior to diagnostic or therapeutic procedures that require a clean bowel, such as a colonoscopy. The use of the product is strictly governed by a required dilution and hydration protocol. Two separate bottles are needed for a complete preparation.

Administration and Dosing Schedule

The medicine is administered orally and can follow one of two schedules, determined by the doctor and the time of the procedure:

  • Split-Dose Regimen (Preferred): The first bottle is taken the evening before the procedure, and the second bottle is taken the following morning.
  • One-Day Preparation: Both doses are taken on the day before the procedure, following a defined time interval.

Preparation Requirements

Each of the two bottles must be prepared individually:

  1. Dilution: The entire content of one bottle must be diluted in water using the provided cup until the total volume reaches approximately 0.5 liters.
  2. Hydration: After ingesting the 0.5 L diluted solution, the patient must drink an additional 1 liter of authorized clear liquid over the next two hours. This mandatory hydration step is repeated for the second dose.

Fluid Requirements

The total liquid intake required for the complete bowel cleansing is 3 liters (1 L of diluted solution and 2 L of additional clear liquid). Authorized clear liquids include water, tea, coffee (without milk/cream), clear soup, still or fizzy soft drinks, and pulp-free fruit juices (not coloured red or purple).

Recent Clinical Evidence

Izinova: Recent Clinical Evidence

Izinova (Oral Sulfate Solution, OSS), a low-volume, osmotic bowel preparation, is indicated in adults for cleansing the bowel prior to any procedure requiring a clean colon, such as endoscopy, radiological examination, or surgery. The active components—anhydrous sodium sulfate, potassium sulfate, and magnesium sulfate—work by drawing water into the bowel to produce a copious, watery stool, resulting in effective purgation.


Efficacy in Adults

Pivotal Phase III clinical trials demonstrated the non-inferiority of Izinova compared to standard high-volume polyethylene glycol (PEG) plus electrolyte solutions for achieving adequate bowel cleansing. This was confirmed across different dosing regimens, including the split-dose regimen (doses given the evening before and the morning of the procedure) and the day-before regimen. The split-dose method generally resulted in a higher rate of successful preparations overall, and one study noted a higher proportion of excellent preparations with the Izinova split-dose compared to a PEG comparator.


Tolerability and Safety Profile

While efficacy is comparable to standard high-volume preparations, Izinova has been associated with a favorable tolerability profile, primarily due to its reduced total liquid volume. This often translates to better patient acceptability and compliance with the regimen. Gastrointestinal adverse events, such as nausea, vomiting, and abdominal pain/distension, are commonly reported but are typically mild to moderate in intensity. Clinically significant laboratory changes, including electrolyte disturbances, are uncommon when Izinova is used as prescribed with adequate additional clear liquid intake, although it is contraindicated in patients with severe renal insufficiency, congestive heart failure, or existing severe electrolyte imbalances.


Real-World Use and Paediatric Studies

Post-marketing observational studies conducted in a real-life European setting affirmed good compliance with the prescribed hydration guidelines and showed a safety profile consistent with the initial clinical trials. Further research has investigated Izinova in adolescents (12–17 years) undergoing colonoscopy. While a non-inferiority in cleansing efficacy to PEG was not universally established in this population, Izinova was often superior in terms of tolerability and patient preference in these younger subjects.

Frequently Asked Questions (FAQ)

Common questions about Izinova (FAQ)

Q: How long does it usually take for Izinova to start working?

A: Izinova is a type of osmotic purgative designed to produce rapid bowel evacuation. Official product information indicates that the start of the intended action—which is the onset of bowel movements—typically occurs within one to three hours after taking the first dose.


Q: Can I stop taking Izinova once my symptoms improve?

A: Izinova is specifically meant for complete cleansing of the bowel before a medical procedure. To ensure the procedure can be performed successfully, the full prescribed regimen of the two bottles is necessary. It is not intended for use that is stopped early based on a patient's temporary feeling of 'improvement.'


Q: Are there any foods or drinks I should avoid while using Izinova?

A: Yes. According to the preparation instructions, the avoidance of solid food is required, and consumption is limited only to the authorized clear liquids. Alcohol consumption is also restricted during this time due to the increased potential for dehydration.


Q: What is the difference between Izinova and [similar drug X]?

A: Official studies compared Izinova to other high-volume preparations used for bowel cleansing. The product information indicates a key difference is the reduced total liquid volume necessary for the preparation, while clinical efficacy was determined to be comparable.


Q: What is the maximum amount of time I can take Izinova for?

A: Izinova is categorized as an acute, short-term medication for pre-procedural bowel cleansing only. The entire regimen, which consists of two bottles, is designed to be completed in less than 24 hours. Official sources do not support its use for long-term or chronic conditions.


Q: Can I take pain relievers while using Izinova?

A: Regulatory documents advise caution regarding the use of certain pain relievers, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The combination carries a potential increased risk of changes in serum chemistry (blood electrolyte levels).


Q: Does Izinova affect mood or cause anxiety?

A: Official reports on adverse reactions primarily list effects like fatigue and headache in the nervous system. Changes in mood or anxiety are not commonly or very commonly reported adverse events according to regulatory documents.


Q: Does Izinova need to be taken with food?

A: No. Izinova is a liquid concentrate that must be diluted in water and consumed with additional clear liquids. Solid food is typically restricted or prohibited during the entire preparation window.


Q: Is it normal to have mild stomach upset when starting Izinova?

A: According to official documentation, effects like abdominal distension, abdominal pain, and nausea are listed as 'very common' reactions. These are typically expected consequences of the cleansing process and are usually mild to moderate in severity.


Q: Can I take Izinova before surgery?

A: Yes. Izinova is formally indicated for use in adults for bowel cleansing before both diagnostic and therapeutic procedures that require a clean bowel. This includes certain types of surgical interventions.


Q: What is the reason Izinova has a warning for [specific condition]?

A: Official warnings and contraindications exist because Izinova works by causing rapid shifts in fluid and electrolytes in the body. This mechanism could potentially complicate or worsen certain pre-existing conditions, such as severe renal impairment or congestive heart failure.


Q: Are the side effects of Izinova permanent?

A: Official reports indicate that the side effects associated with Izinova are generally transient (temporary). The majority of reported adverse events are expected to resolve naturally after the procedure is finished and normal eating and drinking resumes.


Q: How is Izinova eliminated from the body?

A: The sulfate salts that make up the active ingredient of Izinova are intentionally designed to be poorly absorbed into the body’s circulation. The vast majority of the dose is thus eliminated directly from the gastrointestinal tract through the expected process of catharsis (bowel evacuation).


Q: Can Izinova be taken with herbal remedies?

A: Izinova's action significantly speeds up the transit of content through the gastrointestinal tract, which can cause reduced absorption of nearly all oral products. Therefore, all oral products, including herbal remedies, must be separated from Izinova doses by the required time interval (one to six hours).


Q: Are the initial side effects of Izinova supposed to go away?

A: Yes, the common initial side effects are a temporary result of the intensive bowel cleansing. Official documents state these common effects are typically mild to moderate and are expected to resolve once the preparation is complete and the patient returns to a normal diet and hydration.


Q: Does Izinova require special monitoring or blood tests?

A: Official documents advise that monitoring of fluid levels and electrolytes in the blood may be necessary for certain patients. This is particularly true for individuals identified as being at a higher risk of imbalance, such as older adults or those with pre-existing heart or kidney conditions.


Q: How soon after stopping Izinova can I start taking [specific interacting drug]?

A: The official instructions for certain oral medications that bind to cations, such as Digoxin, require a specific timing separation. To ensure proper absorption, these medications must be administered at least 6 hours after the last dose of Izinova.

How should Izinova be stored and disposed of?

How to Store and Dispose of Izinova?

Izinova should be stored at room temperature, away from direct heat and moisture. Do not store it in the bathroom. Keep the medication in its original container and ensure the bottle is tightly capped when not in use.

Storage and Disposal Guidelines

Action Recommended Practice
Storage Temperature Room temperature (typically 68 F to 77 F or 20 C to 25 C)
Protection Store away from light, heat, and moisture
Disposal Follow local medication take-back programs or consult a pharmacist for guidance. Do not flush down a toilet or pour down a drain unless instructed to do so.

Check the expiration date on the packaging and safely dispose of any unused or expired medication. Keep all medicines out of the sight and reach of children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Izinova  found in:

A-Z Index: